Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug in the United States: a mathematical model using data from the C-EDGE CO-STAR study | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug in the United States: a mathematical model using data from the C-EDGE CO-STAR study

Jiang Y, Nwankwo C. Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug in the United States: a mathematical model using data from the C-EDGE CO-STAR study. Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC.

Publication Type:

Conference Proceedings

Authors:

Jiang, Y; Nwankwo, C.

Source:

Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC (0)

Cited On:

Key Populations: Identification and Management of HCV in People Who Inject Drugs

External Third-party Web Link:

http://www.natap.org/2017/AASLD/AASLD_07.htm

Export Citation:

RIS Format

Top